Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$1.9 million.

  • Eton Pharmaceuticals' Income from Continuing Operations fell 40733.65% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 2191.21%. This contributed to the annual value of -$3.8 million for FY2024, which is 30844.02% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Income from Continuing Operations stood at -$1.9 million, which was down 40733.65% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Income from Continuing Operations peaked at $5.1 million during Q1 2021, and registered a low of -$6.1 million during Q3 2021.
  • For the 5-year period, Eton Pharmaceuticals' Income from Continuing Operations averaged around -$1.1 million, with its median value being -$1.6 million (2025).
  • As far as peak fluctuations go, Eton Pharmaceuticals' Income from Continuing Operations soared by 39261.87% in 2023, and later crashed by 40733.65% in 2025.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Income from Continuing Operations stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then plummeted by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$2.6 million for Q2 2025, and -$1.6 million during Q1 2025.